Serial lipoprotein(a) measurements reclassify cardiovascular risk and identify additional candidates for lipoprotein(a)-lowering therapy
Lipoprotein(a) (Lp(a)) has emerged as an important cardiovascular risk factor and is expected to become modifiable through several Lp(a)-lowering therapies in the near future. Current guidelines recommend measuring Lp(a) at least once in a lifetime, as levels are considered largely genetically determined. However...